Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04844424
Recruitment Status : Recruiting
First Posted : April 14, 2021
Last Update Posted : March 2, 2022
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the relative bioavailability and food effect of a single dose of milvexian administered as direct compression (DC) oral tablets and roller compacted (RC) oral tablets compared with milvexian administered as Phase 2 oral capsules (Part 1) and of new concept tablets consisting of a single dose of milvexian administered as oral Tablet 1 and Tablet 2 compared with milvexian administered as Phase 2 oral capsules (Part 3) in healthy participants under fasting and fed conditions; to characterize the pharmacokinetics (PK) of multiple twice daily (BID) doses for 5 days of milvexian administered as DC oral tablets and Phase 2 oral capsules in healthy participants (Part 2) and to assess the effects of dosing time and food timing on the PK of single-dose of milvexian Phase 3 oral tablet formulation in healthy participants (Part 4) and to evaluate the relative bioavailability of a single dose of milvexian administered as oral film-coated DC whole tablets, oral film-coated DC tablets dispersed in water and then mixed with apple sauce, and oral film-coated DC tablets dispersed in water and administered as a suspension using a nasogastric (NG) tube in healthy participants under fasting conditions (Part 5).

Condition or disease Intervention/treatment Phase
Healthy Drug: Milvexian Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label, Randomized, Crossover Study to Evaluate the Relative Oral Bioavailability, Pharmacokinetics, and Food Effect After Single Dose (for Part 1, Part 3, Part 4 and Part 5) or Multiple-Dose (for Part 2) Administration of JNJ-70033093 (Milvexian) in Healthy Adult Participants Using Tablet, Capsule and Dispersed Tablet Formulations
Actual Study Start Date : April 14, 2021
Estimated Primary Completion Date : August 12, 2022
Estimated Study Completion Date : August 12, 2022
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part 1A: Treatment Sequence ABC
Participants will receive a single oral Dose 1 of milvexian as direct compression (DC) tablets under fasting conditions (Treatment A) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as roller compacted (RC) tablets under fasting conditions (Treatment B) in Treatment Period 2 and then a single oral Dose 1 of milvexian Phase 2 oral capsules under fasting conditions (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence BCA
Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence CAB
Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence ACB
Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence BAC
Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence CBA
Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence DEF
Participants will receive a single oral Dose 1 of milvexian as DC oral tablets under fed conditions (Treatment D) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as RC oral tablets under fed conditions (Treatment E) in Treatment Period 2 and then a single oral Dose 1 of milvexian as Phase 2 oral capsules under fed conditions (Treatment F) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence EFD
Participants will receive Treatment E in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence FDE
Participants will receive Treatment F in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence DFE
Participants will receive Treatment D in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence EDF
Participants will receive Treatment E in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment F in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence FED
Participants will receive Treatment F in Treatment Period 1, followed by Treatment E in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 2A: Treatment Sequence GH
Participants will receive twice daily (BID) oral Dose 1 of milvexian DC oral tablets (Treatment G) in Treatment Period 1, followed by BID oral Dose 1 of milvexian Phase 2 oral capsule (Treatment H) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 2A: Treatment Sequence HG
Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 2B: Treatment Sequence IJ
Participants will receive BID oral Dose 2 of milvexian DC oral tablet (Treatment I) in Treatment Period 1, followed by BID oral Dose 2 of milvexian Phase 2 oral capsule (Treatment J) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 2B: Treatment Sequence JI
Participants will receive Treatment J in Treatment Period 1, followed by Treatment I in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence KLM
Participants will receive single oral Dose 1 of milvexian as oral Tablet 1 under fasting conditions (Treatment K) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fasting conditions (Treatment L) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 2 oral capsules under fasting conditions (Treatment M) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence LMK
Participants will receive Treatment L in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 of each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence MKL
Participants will receive Treatment M in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence KML
Participants will receive Treatment K in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence LKM
Participants will receive Treatment L in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment M in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence MLK
Participants will receive Treatment M in Treatment Period 1, followed by Treatment L in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence NOP
Participants will receive single oral Dose 1 of milvexian oral Tablet 1 under fed conditions (Treatment N) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fed conditions (Treatment O) in Treatment Period 2 and then single oral Dose 1 of milvexian Phase 2 oral capsule under fed conditions (Treatment P) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence OPN
Participants will receive Treatment O in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence PNO
Participants will receive Treatment P in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence NPO
Participants will receive Treatment N in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence ONP
Participants will receive Treatment O in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment P in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence PON
Participants will receive Treatment P in Treatment Period 1, followed by Treatment O in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4 A: Treatment Sequence QRS
Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablets under fasting conditions (Treatment Q) in Treatment Period 1, followed by single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment R) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment S) in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence RSQ
Participants will receive Treatment R in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence SQR
Participants will receive Treatment S in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence QSR
Participants will receive Treatment Q in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence RQS
Participants will receive Treatment R in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment S in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence SRQ
Participants will receive Treatment S in Treatment Period 1, followed by Treatment R in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4B: Treatment Sequence TU
Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablet under fed conditions (Treatment T) in Treatment Period 1, followed by single oral Dose 2 of milvexian as Phase 3 oral tablet under fed conditions (Treatment U) in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 4B: Treatment Sequence UT
Participants will receive Treatment U in Treatment Period 1, followed by Treatment T in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Subpart 4A: Treatment Sequence VW
All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive milvexian tablet dispersed in water without a sweetener orally via syringe (Treatment V) in Treatment Period 1, followed by milvexian tablet dispersed in water with sucralose sweetener orally via syringe (Treatment W) in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Subpart 4A: Treatment Sequence WV
All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive Treatment W in Treatment Period 1, followed by Treatment V in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence XYZ
Participants will receive a single oral Dose 1 of milvexian as DC whole tablets under fasting conditions (Treatment X) in Treatment Period 1 followed by a single oral Dose 1 of milvexian as DC tablets dispersed in water and then mixed with apple sauce under fasting conditions (Treatment Y) in Treatment Period 2 and then a single oral Dose 1 of milvexian as DC tablets dispersed in water administered through a nasogastric (NG) tube under fasting conditions (Treatment Z) in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence YZX
Participants will receive Treatment Y in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence ZXY
Participants will receive Treatment Z in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence XZY
Participants will receive Treatment X in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence YXZ
Participants will receive Treatment Y in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Z in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence ZYX
Participants will receive Treatment Z in Treatment Period 1 followed by Treatment Y in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
 Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Name: JNJ-70033093, BMS-986177


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Area Under the Plasma Concentration-time Curve of Milvexian from Time Zero to Infinity (AUC [0-Infinity]) [ Time Frame: Up to 16 months ]
    AUC (0-infinity) is defined as area under the plasma concentration-time curve of milvexian from time zero to infinity after administration.

  2. Part 2: Area under the Plasma Concentration-time Curve of Milvexian From Time Zero to Time of Last Quantifiable Concentration (AUC [0-Last]) [ Time Frame: Up to 16 months ]
    AUC (0-last) is defined as area under the plasma concentration-time curve of milvexian from time zero to time of last quantifiable concentration after administration.

  3. Maximum Observed Analyte Concentration (Cmax) of Milvexian [ Time Frame: Up to 16 months ]
    Cmax is defined as maximum observed analyte concentration of milvexian.

  4. Parts 1 and 3: AUC (0-Infinity) of Milvexian (Food effect) [ Time Frame: Up to 16 months ]
    AUC (0-infinity) is defined as area under the plasma concentration-time curve of milvexian from time zero to infinity after administration.

  5. Parts 1 and 3: AUC (0-Last) of Milvexian (Food effect) [ Time Frame: Up to 16 months ]
    AUC (0-last) is defined as area under the plasma concentration-time curve of milvexian from time zero to time of last quantifiable concentration after administration.

  6. Parts 1 and 3: Cmax of Milvexian (Food effect) [ Time Frame: Up to 16 months ]
    Cmax is defined as maximum observed analyte concentration of milvexian.

  7. Actual Sampling Time to Reach the Maximum Observed Analyte Concentration (Tmax) of Milvexian [ Time Frame: Up to 16 months ]
    Tmax is defined as the actual sampling time to reach the maximum observed analyte concentration of milvexian.

  8. Parts 1 and 3: Tmax of Milvexian (Food effect) [ Time Frame: Up to 16 months ]
    Tmax is defined as the actual sampling time to reach the maximum observed analyte concentration of milvexian.


Secondary Outcome Measures :
  1. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability [ Time Frame: Up to 16 months ]
    An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and on Day -1 of Treatment Period 1. If there are abnormalities, the investigator may decide that the abnormalities or deviations from normal are not clinically significant, in which case the participant may be included
  • Body mass index (BMI equals to [=] weight/height^2) between 18 and 30 kilograms per meter square (kg/m^2) (inclusive), and body weight not less than 50 kg at screening
  • Healthy on the basis of safety laboratory tests performed at screening and on Day -1 of Treatment Period 1. If the results of the safety laboratory tests are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant except as specified in Exclusion Criteria 2. This determination must be recorded in the participant's source documents and initialed by the investigator
  • A woman must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and urine pregnancy test on Day 1 of Treatment Period 1
  • Before randomization, a woman must be either: a) Not of childbearing potential defined as: postmenopausal: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level greater than (>) 40 international units per liter IU/L or milli-international units per milliliter (mIU/mL) in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal replacement therapy (HRT), however in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient; permanently sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; b) Of childbearing potential and; practicing a highly effective method of contraception (failure rate of less than [<] 1 percent [%] per year when used consistently and correctly) for at least 3 months prior to the study entry and; agrees to remain on a highly effective method of contraception throughout the study and for at least 34 days after the last dose of study drug
  • During the study, a man who is sexually active with a woman of childbearing potential or with a woman who is pregnant must agree to use a barrier method of contraception (example, condom with spermicidal foam/gel/ film/cream/suppository)

Exclusion Criteria:

  • History of any known illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant or that could prevent, limit or confound the protocol-specified assessments. This may include but is not limited to any known bleeding or clotting disorder, a history of arterial or venous thrombosis, liver or renal dysfunction, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, neoplasm, metabolic disturbances, or poor venous access
  • Clinically significant abnormal values for hematology, coagulation, clinical chemistry, or urinalysis at screening or on Day -1 of Treatment Period 1 as determined by the investigator or appropriate designee. Any of the following laboratory results outside of the normal ranges specified below at screening or Day -1 of Treatment Period 1 which must be confirmed by repeat: Hemoglobin or hematocrit less than (<) lower limit of normal; Platelet count < lower limit of normal; activated partial thromboplastin time (aPTT) or prothrombin time (PT) >1.2*upper limit of normal (ULN)
  • Use of any agent, including but not limited to non-steroidal anti-inflammatory drugs (NSAIDs), aspirin or other anti-platelet agents, anticoagulants, fish oil capsules, ginkgo or any agent that can potentially increase the risk of bleeding within 14 days prior to the first dose of study drug administration
  • History of any clinically significant drug or food allergies (such as anaphylaxis or hepatotoxicity) and known allergy to the study drugs or any of the excipients of the formulation
  • History of allergy to or unwillingness to consume any component of the standardized high-fat breakfast menu to be provided in this study
  • Woman with history of excessive menstrual bleeding as determined by the investigator or appropriate designee
  • Does not tolerate venipuncture
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04844424


Contacts
Layout table for location contacts
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com

Locations
Layout table for location information
United States, Utah
PRA Health Sciences Recruiting
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT04844424    
Other Study ID Numbers: CR108999
70033093THR1008 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: April 14, 2021    Key Record Dates
Last Update Posted: March 2, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No